NM_001365536.1:c.5351delA
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_001365536.1(SCN9A):c.5351delA(p.Glu1784GlyfsTer14) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000657 in 152,146 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_001365536.1 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCN9A | NM_001365536.1 | c.5351delA | p.Glu1784GlyfsTer14 | frameshift_variant | Exon 27 of 27 | ENST00000642356.2 | NP_001352465.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN9A | ENST00000642356.2 | c.5351delA | p.Glu1784GlyfsTer14 | frameshift_variant | Exon 27 of 27 | NM_001365536.1 | ENSP00000495601.1 | |||
SCN9A | ENST00000303354.11 | c.5351delA | p.Glu1784GlyfsTer14 | frameshift_variant | Exon 27 of 27 | 5 | ENSP00000304748.7 | |||
SCN9A | ENST00000409672.5 | c.5318delA | p.Glu1773GlyfsTer14 | frameshift_variant | Exon 27 of 27 | 5 | ENSP00000386306.1 | |||
SCN9A | ENST00000645907.1 | c.5318delA | p.Glu1773GlyfsTer14 | frameshift_variant | Exon 27 of 27 | ENSP00000495983.1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152146Hom.: 0 Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 0.0000226 AC: 33AN: 1461894Hom.: 0 Cov.: 32 AF XY: 0.0000165 AC XY: 12AN XY: 727248
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152146Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74312
ClinVar
Submissions by phenotype
Inborn genetic diseases Pathogenic:1
The c.5318delA (p.E1773Gfs*14) alteration, located in exon 27 (coding exon 26) of the SCN9A gene, consists of a deletion of one nucleotide at position 5318, causing a translational frameshift with a predicted alternate stop codon after 14 amino acids. This alteration occurs at the 3' terminus of the SCN9A gene, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 10.4% of the protein. Premature stop codons are typically deleterious in nature and a significant portion of the protein is affected (Ambry internal data). _x000D_ _x000D_ Based on the available evidence, the SCN9A c.5318delA (p.E1773Gfs*14) alteration is classified as likely pathogenic for autosomal recessive congenital insensitivity to pain; however, its clinical significance for autosomal dominant SCN9A-related neuropathic pain syndromes is unclear. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been reported compound heterozygous with c.2488C>T (p.R830*) in an individual with congenital insensitivity to pain and anosmia (Ramirez, 2014; McDermott, 2019) . An in vitro functional analysis of this variant has shown a significant reduction in protein function compared to wild-type (McDermott, 2019). Based on the available evidence, this alteration is classified as likely pathogenic. -
Channelopathy-associated congenital insensitivity to pain, autosomal recessive Pathogenic:1
Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Likely pathogenic. Following criteria are met: 0103 - Loss of function and gain of function are known mechanisms of disease in this gene. Loss of function variants are associated with congenital insensitivity to pain (MIM#243000); gain of function variants are associated with primary erythermalgia (MIM#133020) and paroxysmal extreme pain disorder (MIM#167400) (PMID: 18060017). (I) 0108 - This gene is associated with both recessive and dominant disease. Type IID hereditary sensory and autonomic neuropathy, and congenital insensitivity to pain (MIM#243000) are associated with autosomal recessive inheritance; primary erythermalgia and small fiber neuropathy (MIM#133020), and paroxysmal extreme pain disorder (MIM#167400) are inherited in an autosomal dominant pattern (OMIM). (I) 0112 - The condition associated with this gene has incomplete penetrance. Small fiber neuropathy is associated with reduced penetrance (PMID: 20301342). (I) 0205 - Variant is predicted to result in a truncated protein (premature termination codon is NOT located at least 54 nucleotides upstream of the final exon-exon junction) with less than 1/3 of the protein sequence affected. (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v3) <0.01 (1 heterozygote, 0 homozygotes). (SP) 0604 - There is no annotated protein domain located downstream of this variant (DECIPHER). (I) 0708 - Other premature termination variants (PTVs) comparable to the one identified in this case have conflicting previous evidence for pathogenicity. PTVs located downstream of this variant had been reported in individuals with congenital insensitivity to pain (PMIDs: 28494607, 25995458), and as likely pathogenic or uncertain significance in ClinVar. (I) 0803 - This variant has limited previous evidence of pathogenicity in an unrelated individual. It has been reported in two affected siblings as compound heterozygous with an NMD-predicted variant (PMID: 25253744). It has also been reported as pathogenic once in ClinVar. (SP) 1007 - No published functional evidence has been identified for this variant. (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -
Generalized epilepsy with febrile seizures plus, type 7;C2752089:Neuropathy, hereditary sensory and autonomic, type 2A Pathogenic:1
This sequence change creates a premature translational stop signal (p.Glu1773Glyfs*14) in the SCN9A gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 205 amino acid(s) of the SCN9A protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with congenital insensitivity to pain (PMID: 25253744). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 471143). Algorithms developed to predict the effect of variants on gene product structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects SCN9A function (PMID: 30795902). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:1
Published functional studies demonstrate significantly reduced current density of the channel resulting in almost complete loss of channel function (McDermott et al., 2019); Frameshift variant predicted to result in protein truncation, as the last 205 amino acids are replaced with 13 different amino acids, and other loss-of-function variants have been reported downstream in HGMD; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25253744, 30795902) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at